Arxis, Inc. is a clinical-stage biotechnology company dedicated to the development and commercialization of innovative therapies for patients suffering from respiratory diseases. The company's primary focus is on addressing significant unmet medical needs in conditions such as chronic obstructive pulmonary disease (COPD) and asthma. Arxis leverages its proprietary technology platform to design and develop novel drug candidates that target specific biological pathways involved in respiratory inflammation and airway remodeling. Its lead product candidate, ARX-101, is an inhaled small molecule being evaluated for its potential to improve lung function and reduce exacerbations in patients with severe respiratory conditions. By utilizing a lung-targeted drug delivery approach, Arxis aims to maximize therapeutic efficacy at the site of disease while minimizing systemic side effects. The company's strategy involves advancing its clinical pipeline through rigorous testing and seeking regulatory approvals to bring life-changing treatments to a global patient population. Arxis is headquartered in the United States and continues to invest in research and development to expand its portfolio of respiratory-focused therapeutics.